The agreements involve firms representing 93% of the pending cases in the U.S. The firms are advising their clients to accept the settlement, which is expected to be finalized by mid-2025, according to an Oct. 9 news release from the company.
In addition to the settlement, GSK agreed to pay $70 million to resolve a qui tam complaint filed by testing laboratory Valisure, pending approval from the Justice Department.
While the settlements are not an admission of liability on the part of GSK, the drugmaker said the agreements are in its long-term interest, the release said.
A Chicago jury failed to reach a verdict Sept. 18 over claims that Zantac causes cancer.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
